317 related articles for article (PubMed ID: 28776577)
1. Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.
Pai RK; Pai RK
Mod Pathol; 2018 Jan; 31(1):4-23. PubMed ID: 28776577
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
Loehrer AP; Kinnier CV; Ferrone CR
Adv Surg; 2016 Sep; 50(1):115-28. PubMed ID: 27520867
[No Abstract] [Full Text] [Related]
3. [The neoadjuvant treatment of gastrointestinal tumors: time for rethinking?].
Ebert MP; Schmid RM
Dtsch Med Wochenschr; 2009 Sep; 134(37):1835-7. PubMed ID: 19728255
[No Abstract] [Full Text] [Related]
4. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis.
Zhao Q; Rashid A; Gong Y; Katz MH; Lee JE; Wolf R; Balachandran A; Varadhachary GR; Pisters PW; Wang H; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
Ann Diagn Pathol; 2012 Jan; 16(1):29-37. PubMed ID: 22050964
[TBL] [Abstract][Full Text] [Related]
5. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.
Estrella JS; Rashid A; Fleming JB; Katz MH; Lee JE; Wolf RA; Varadhachary GR; Pisters PW; Abdalla EK; Vauthey JN; Wang H; Gomez HF; Evans DB; Abbruzzese JL; Wang H
Cancer; 2012 Jan; 118(1):268-77. PubMed ID: 21735446
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.
Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H
Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394
[TBL] [Abstract][Full Text] [Related]
7. The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract.
Matuschek C; Bölke E; Peiper M; Knoefel WT; Budach W; Erhardt A; Scherer A; Gerber PA; Buhren BA; Gattermann N; Baldus SE; Rusnak E; Shukla V; Orth K
Eur J Med Res; 2011 Jun; 16(6):265-74. PubMed ID: 21810561
[TBL] [Abstract][Full Text] [Related]
8. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.
Tsai S; Christians KK; George B; Ritch PS; Dua K; Khan A; Mackinnon AC; Tolat P; Ahmad SA; Hall WA; Erickson BA; Evans DB
Ann Surg; 2018 Oct; 268(4):610-619. PubMed ID: 30080723
[TBL] [Abstract][Full Text] [Related]
9. Nodal downstaging as a treatment goal for node-positive pancreatic cancer.
Portuondo JI; Massarweh NN; Zhang Q; Chai CY; Tran Cao HS
Surgery; 2019 Jun; 165(6):1144-1150. PubMed ID: 30745009
[TBL] [Abstract][Full Text] [Related]
10. Morphologic changes associated with neoadjuvant-treated pancreatic ductal adenocarcinoma and comparison of two tumor regression grading systems.
Vazzano J; Frankel WL; Wolfe AR; Williams TM; Chen W
Hum Pathol; 2021 Mar; 109():1-11. PubMed ID: 33245985
[TBL] [Abstract][Full Text] [Related]
11. Stroma composition and proliferative activity are related to therapy response in neoadjuvant treated pancreatic ductal adenocarcinoma.
Haeberle L; Cacciato Insilla A; Kapp AC; Steiger K; Schlitter AM; Konukiewitz B; Demir IE; Friess H; Esposito I
Histol Histopathol; 2021 Jul; 36(7):733-742. PubMed ID: 33769550
[TBL] [Abstract][Full Text] [Related]
12. Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes.
Zhang ML; Kem M; Rodrigues C; Sandini M; Ciprani D; Hank T; Kunitoki K; Qadan M; Ferrone C; Lillemoe K; Fernández-Del Castillo C; Mino-Kenudson M
Histopathology; 2020 Jul; 77(1):144-155. PubMed ID: 31965618
[TBL] [Abstract][Full Text] [Related]
13. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
14. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival.
Panda A; Garg I; Truty MJ; Kline TL; Johnson MP; Ehman EC; Suman G; Anaam DA; Kemp BJ; Johnson GB; Halfdanarson TR; Venkatesh SK; Fidler JL; Goenka AH
AJR Am J Roentgenol; 2021 Sep; 217(3):730-740. PubMed ID: 33084382
[No Abstract] [Full Text] [Related]
15. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis.
Timmermann L; Rosumeck N; Klein F; Pratschke J; Pelzer U; Bahra M; Malinka T
Anticancer Res; 2019 Oct; 39(10):5781-5787. PubMed ID: 31570482
[TBL] [Abstract][Full Text] [Related]
16. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.
Kircher SM; Krantz SB; Nimeiri HS; Mulcahy MF; Munshi HG; Benson AB
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1555-65. PubMed ID: 21999129
[TBL] [Abstract][Full Text] [Related]
17. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
[TBL] [Abstract][Full Text] [Related]
18. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings.
Badiyan SN; Molitoris JK; Chuong MD; Regine WF; Kaiser A
Surg Oncol Clin N Am; 2017 Jul; 26(3):431-453. PubMed ID: 28576181
[TBL] [Abstract][Full Text] [Related]
19. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
Keane FK; Wo JY; Ferrone CR; Clark JW; Blaszkowsky LS; Allen JN; Kwak EL; Ryan DP; Lillemoe KD; Fernandez-Del Castillo C; Hong TS
Am J Clin Oncol; 2018 Jun; 41(6):607-612. PubMed ID: 27740973
[TBL] [Abstract][Full Text] [Related]
20. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems.
Matsuda Y; Ohkubo S; Nakano-Narusawa Y; Fukumura Y; Hirabayashi K; Yamaguchi H; Sahara Y; Kawanishi A; Takahashi S; Arai T; Kojima M; Mino-Kenudson M
Sci Rep; 2020 Oct; 10(1):18278. PubMed ID: 33106543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
